Hilleman Laboratories was established in 2009 as an equal joint venture between Merck Sharp & Dohme Corp. (MSD), a global research-driven pharmaceutical company and Wellcome Trust, a global charitable foundation dedicated to health. Hilleman Laboratories’ mission is to develop affordable vaccines and biologics against infectious diseases that affect low- and middle-income countries. Hilleman Laboratories is establishing a first-of-its-kind vaccine and biologics development and manufacturing hub in Singapore comprising a 30,000 square foot current Good Manufacturing Practices (cGMP) facility and a state-of-the-art research and development facility.